Charles River and Takeda will together identify and develop preclinical develops under a new multi-year drug discovery collaboration.
The companies will launch multiple integrated programmes across Takeda’s four core therapeutic areas – oncology, gastroenterology, neuroscience, and rare disease – with the aim of delivering preclinical candidates that can be advanced into clinical development.
Charles River will leverage its end-to-end drug discovery and safety assessment platform to explore potential therapeutic approaches and progress these programs towards candidate status. Takeda will then have the option to advance the preclinical candidates through their clinical development pipeline.
Takeda will pay Charles River a one-time, upfront fee to establish the collaboration.
Charles River will also be eligible to receive development payments with a potential value of over $50 million per program in preclinical and clinical milestones for candidates that progress to registration.
The agreement also includes additional potential commercial milestones of up to $120 million plus royalties on launched products.